Steve Schoonooghe

This inventor holds 5 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Vib Vzw, Vrije Universiteit Brussel. Active years: 2015-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steve Schoonooghe. Retrieved from https://idiyas.com/inventor/steve-schoonooghe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

Vrije Universiteit Brussel

patents

where one patent can have more than one assignee

Years Active: 2015-2021

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11155607 - Serum albumin binding agents (2021-10-26),

2. 9913920 - Targeting and in vivo imaging of tumor-associated macrophages (2018-03-13),

3. 9617339 - Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain (2017-04-11),

4. 9556273 - Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages (2017-01-31),

5. 9101674 - Targeting and in vivo imaging of tumor-associated macrophages (2015-08-11),

Title: Steve Schoonooghe: Innovator in Therapeutic Agents and Cancer Diagnostics

Introduction

Steve Schoonooghe is a notable inventor based in Kessel-lo, Belgium. He has made significant contributions to the field of therapeutic agents and cancer diagnostics, holding a total of five patents. His work focuses on enhancing the efficacy of treatments through innovative binding agents and imaging techniques.

Latest Patents

One of Schoonooghe's latest patents is related to serum albumin binding agents. This invention involves polypeptides that comprise an immunoglobulin variable domain, which binds with high affinity to serum albumin. This technology aims to increase the half-life of therapeutic agents, particularly those that include multispecific immunoglobulin variable domains. Additionally, he has developed methods for producing these polypeptides, which are crucial for advancing therapeutic applications.

Another significant patent addresses the targeting and in vivo imaging of tumor-associated macrophages (TAMs). This disclosure focuses on the activities and characteristics of TAMs, providing immunoglobulin single variable domains against specific markers. The methods developed using these domains are intended for in vivo imaging of tumor cells, as well as for cancer diagnostics and therapeutics.

Career Highlights

Throughout his career, Schoonooghe has worked with reputable organizations, including Vib Vzw and Vrije Universiteit Brussel. His experience in these institutions has allowed him to collaborate on various innovative projects that push the boundaries of medical science.

Collaborations

Schoonooghe has collaborated with esteemed colleagues such as Geert Raes and Patrick De Baetselier. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Steve Schoonooghe is a prominent figure in the field of therapeutic innovations and cancer diagnostics. His patents reflect a commitment to improving medical treatments and enhancing patient outcomes. His work continues to inspire advancements in the medical community.

Profile summary based on public USPTO records.